127 related articles for article (PubMed ID: 24357745)
1. Epidermal growth factor receptor inhibitors: coming of age.
Mahipal A; Kothari N; Gupta S
Cancer Control; 2014 Jan; 21(1):74-9. PubMed ID: 24357745
[TBL] [Abstract][Full Text] [Related]
2. A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers.
Urban C; Anadkat MJ
J Gastrointest Oncol; 2013 Sep; 4(3):319-27. PubMed ID: 23997943
[TBL] [Abstract][Full Text] [Related]
3. Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations.
Haspinger ER; Agustoni F; Torri V; Gelsomino F; Platania M; Zilembo N; Gallucci R; Garassino MC; Cinquini M
Crit Rev Oncol Hematol; 2015 May; 94(2):213-27. PubMed ID: 25523487
[TBL] [Abstract][Full Text] [Related]
4. The Mysterious Ways of ErbB2/HER2 Trafficking.
Bertelsen V; Stang E
Membranes (Basel); 2014 Aug; 4(3):424-46. PubMed ID: 25102001
[TBL] [Abstract][Full Text] [Related]
5. Triple-negative breast carcinoma: current and emerging concepts.
Schmadeka R; Harmon BE; Singh M
Am J Clin Pathol; 2014 Apr; 141(4):462-77. PubMed ID: 24619745
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy targeting the EGFR oncogene in NSCLC.
Landi L; Cappuzzo F
Expert Opin Pharmacother; 2014 Nov; 15(16):2293-305. PubMed ID: 25219817
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.
Janjigian YY; Smit EF; Groen HJ; Horn L; Gettinger S; Camidge DR; Riely GJ; Wang B; Fu Y; Chand VK; Miller VA; Pao W
Cancer Discov; 2014 Sep; 4(9):1036-45. PubMed ID: 25074459
[TBL] [Abstract][Full Text] [Related]
8. Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer.
Lee CC; Shiao HY; Wang WC; Hsieh HP
Expert Opin Investig Drugs; 2014 Oct; 23(10):1333-48. PubMed ID: 24921970
[TBL] [Abstract][Full Text] [Related]
9. The Potential of panHER Inhibition in Cancer.
Wang X; Batty KM; Crowe PJ; Goldstein D; Yang JL
Front Oncol; 2015; 5():2. PubMed ID: 25674538
[TBL] [Abstract][Full Text] [Related]
10. Prediction of signaling cross-talks contributing to acquired drug resistance in breast cancer cells by Bayesian statistical modeling.
Azad AK; Lawen A; Keith JM
BMC Syst Biol; 2015 Jan; 9():2. PubMed ID: 25599599
[TBL] [Abstract][Full Text] [Related]
11. Hereditary breast cancer: clinical, pathological and molecular characteristics.
Larsen MJ; Thomassen M; Gerdes AM; Kruse TA
Breast Cancer (Auckl); 2014; 8():145-55. PubMed ID: 25368521
[TBL] [Abstract][Full Text] [Related]
12. Targeting metastatic colorectal cancer - present and emerging treatment options.
Ciombor KK; Berlin J
Pharmgenomics Pers Med; 2014; 7():137-44. PubMed ID: 25045279
[TBL] [Abstract][Full Text] [Related]
13. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.
Seiwert TY; Fayette J; Cupissol D; Del Campo JM; Clement PM; Hitt R; Degardin M; Zhang W; Blackman A; Ehrnrooth E; Cohen EEW
Ann Oncol; 2014 Sep; 25(9):1813-1820. PubMed ID: 24928832
[TBL] [Abstract][Full Text] [Related]
14. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors.
Roskoski R
Pharmacol Res; 2014 Sep; 87():42-59. PubMed ID: 24928736
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.
Okada Y; Miyamoto H; Goji T; Takayama T
Digestion; 2014; 89(1):18-23. PubMed ID: 24458108
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of action of immunotherapy.
Disis ML
Semin Oncol; 2014 Oct; 41 Suppl 5():S3-13. PubMed ID: 25438997
[TBL] [Abstract][Full Text] [Related]
17. Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe.
Blok EJ; Bastiaannet E; van den Hout WB; Liefers GJ; Smit VTHBM; Kroep JR; van de Velde CJH
Cancer Treat Rev; 2018 Jan; 62():74-90. PubMed ID: 29175678
[TBL] [Abstract][Full Text] [Related]
18. Proteogenomic and metabolomic characterization of human glioblastoma.
Wang LB; Karpova A; Gritsenko MA; Kyle JE; Cao S; Li Y; Rykunov D; Colaprico A; Rothstein JH; Hong R; Stathias V; Cornwell M; Petralia F; Wu Y; Reva B; Krug K; Pugliese P; Kawaler E; Olsen LK; Liang WW; Song X; Dou Y; Wendl MC; Caravan W; Liu W; Cui Zhou D; Ji J; Tsai CF; Petyuk VA; Moon J; Ma W; Chu RK; Weitz KK; Moore RJ; Monroe ME; Zhao R; Yang X; Yoo S; Krek A; Demopoulos A; Zhu H; Wyczalkowski MA; McMichael JF; Henderson BL; Lindgren CM; Boekweg H; Lu S; Baral J; Yao L; Stratton KG; Bramer LM; Zink E; Couvillion SP; Bloodsworth KJ; Satpathy S; Sieh W; Boca SM; Schürer S; Chen F; Wiznerowicz M; Ketchum KA; Boja ES; Kinsinger CR; Robles AI; Hiltke T; Thiagarajan M; Nesvizhskii AI; Zhang B; Mani DR; Ceccarelli M; Chen XS; Cottingham SL; Li QK; Kim AH; Fenyö D; Ruggles KV; Rodriguez H; Mesri M; Payne SH; Resnick AC; Wang P; Smith RD; Iavarone A; Chheda MG; Barnholtz-Sloan JS; Rodland KD; Liu T; Ding L;
Cancer Cell; 2021 Apr; 39(4):509-528.e20. PubMed ID: 33577785
[TBL] [Abstract][Full Text] [Related]
19. Clinical Relevance of RNA Editing to Early Detection of Cancer in Human.
Ullah M; Akbar A
Int J Stem Cell Res Ther; 2020; 7(1):. PubMed ID: 33215051
[TBL] [Abstract][Full Text] [Related]
20. Stroke Disparities: From Observations to Actions: Inaugural Edward J. Kenton Lecture 2020.
Sacco RL
Stroke; 2020 Nov; 51(11):3392-3405. PubMed ID: 33104468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]